Daniel Janney
CIK 1198325 · last filed 2026-09-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KRYS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
JACKSON, WY 83002
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRYS | Director | 74,036 | $304.88 | $22.57M | -$42.01M | 17 | 2026-09-16 |
| Allakos Inc. (ALLK) Delisted | Director | 6,448,053 | $0.33 | $2.12M | $1.22M | 11 | 2023-05-30 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 48,014 | $3.18 | $152.7K | -$2.73M | 11 | 2021-05-28 |
| STRO | Director | 194,490 | $10.09 | $1.96M | $0 | 3 | 2019-06-19 |
| VIVEVE MEDICAL, INC. (VIVE) Delisted | Director | 1,443 | $0.00 | $0 | $3.00M | 16 | 2019-01-02 |
| VIVEVE MEDICAL, INC. (TCON) Delisted | Director | 27,278 | $0.03 | $878 | $1.60M | 4 | 2016-01-29 |
| Evofem Biosciences, Inc. (NEOT) Delisted | Director | 264,963 | — | — | -$1.20M | 2 | 2015-12-30 |
| ZS Pharma, Inc. (ZSPH) Delisted | 10%+ Owner | 2,657,843 | — | — | -$10.15M | 1 | 2015-06-09 |
| ELLIE MAE INC (ELLI) Delisted | 10%+ Owner | 3,407,978 | — | — | -$1.96M | 1 | 2011-04-21 |
| ANESIVA, INC. (ANSV) Delisted | Director | 6,172,840 | — | — | $0 | 3 | 2008-05-12 |
| COTHERIX INC (CTRX) Delisted | Director | — | — | — | $0 | 1 | 2007-01-05 |
Recent Filings · Page 7 of 9
81 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-08-24 | VIVEVE MEDICAL, INC. (VIVE) Delisted | Grant (A) | +1,279 | $0 | EDGAR |
| 2016-06-20 | VIVEVE MEDICAL, INC. (VIVE) Delisted | Buy (P) | +200,000 | $1.00M | EDGAR |
| 2016-06-10 | Esperion Therapeutics, Inc. (ESPR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-01-29 | VIVEVE MEDICAL, INC. (TCON) Delisted | Buy (P) | — | $0 | EDGAR |
| 2015-12-30 | Evofem Biosciences, Inc. (NEOT) Delisted | Sell (S) | −797,987 | -$1.20M | EDGAR |
| 2015-12-18 | VIVEVE MEDICAL, INC. (TCON) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-11-25 | VIVEVE MEDICAL, INC. (TCON) Delisted | Buy (P) | +857,142 | $600.0K | EDGAR |
| 2015-06-17 | Evofem Biosciences, Inc. (NEOT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-09 | ZS Pharma, Inc. (ZSPH) Delisted | Sell (S) | −175,427 | -$10.15M | EDGAR |
| 2015-05-18 | Esperion Therapeutics, Inc. (ESPR) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.